Brokerages predict that uniQure N.V. (NASDAQ:QURE) will report sales of $2.00 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for uniQure N.V.’s earnings. The highest sales estimate is $2.80 million and the lowest is $1.20 million. uniQure N.V. posted sales of $7.21 million in the same quarter last year, which suggests a negative year-over-year growth rate of 72.3%. The company is scheduled to report its next earnings results on Tuesday, November 28th.
On average, analysts expect that uniQure N.V. will report full-year sales of $2.00 million for the current fiscal year, with estimates ranging from $14.00 million to $21.40 million. For the next financial year, analysts anticipate that the business will report sales of $21.90 million per share, with estimates ranging from $13.80 million to $31.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow uniQure N.V..
uniQure N.V. (NASDAQ:QURE) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.05. uniQure N.V. had a negative net margin of 289.94% and a negative return on equity of 131.27%. The company had revenue of $4.94 million for the quarter, compared to the consensus estimate of $2.92 million.
A number of brokerages have issued reports on QURE. Zacks Investment Research downgraded uniQure N.V. from a “buy” rating to a “hold” rating in a report on Thursday, August 24th. Chardan Capital set a $13.00 target price on uniQure N.V. and gave the stock a “buy” rating in a research note on Sunday, July 23rd. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $17.00 price target on shares of uniQure N.V. in a research report on Friday, June 30th. ValuEngine cut uniQure N.V. from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Cowen and Company reiterated a “buy” rating on shares of uniQure N.V. in a research report on Wednesday, May 24th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. uniQure N.V. currently has a consensus rating of “Hold” and an average price target of $12.45.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/09/12/uniqure-n-v-qure-expected-to-announce-quarterly-sales-of-2-00-million.html.
uniQure N.V. (QURE) opened at 8.44 on Tuesday. The stock has a 50 day moving average of $8.25 and a 200 day moving average of $6.38. uniQure N.V. has a 52 week low of $4.72 and a 52 week high of $9.15. The company’s market cap is $215.73 million.
In related news, insider Harald Petry sold 49,300 shares of the firm’s stock in a transaction that occurred on Thursday, June 29th. The stock was sold at an average price of $6.02, for a total transaction of $296,786.00. Following the transaction, the insider now owns 27,753 shares in the company, valued at approximately $167,073.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 173,460 shares of company stock worth $1,042,986 in the last 90 days. 0.73% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the business. Oxford Asset Management acquired a new stake in shares of uniQure N.V. in the 1st quarter valued at approximately $100,000. JPMorgan Chase & Co. raised its holdings in uniQure N.V. by 50.5% during the first quarter. JPMorgan Chase & Co. now owns 43,822 shares of the biotechnology company’s stock worth $253,000 after purchasing an additional 14,702 shares during the last quarter. FMR LLC raised its holdings in uniQure N.V. by 27.5% during the first quarter. FMR LLC now owns 1,498,463 shares of the biotechnology company’s stock worth $8,661,000 after purchasing an additional 323,345 shares during the last quarter. P.A.W. Capital Corp acquired a new position in uniQure N.V. during the first quarter worth $867,000. Finally, Morgan Stanley raised its holdings in uniQure N.V. by 14.9% during the first quarter. Morgan Stanley now owns 565,760 shares of the biotechnology company’s stock worth $3,271,000 after purchasing an additional 73,418 shares during the last quarter. Institutional investors own 29.86% of the company’s stock.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.